Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic myeloma diagnosis according to criteria in attachment 3~* ASCT is performed or has been performed in the last five weeks (time limit two weeks for patients randomised at 2nd transplantation) as a part of primary therapy~* Signed informed consent given prior to any study related activities have been performed~Exclusion Criteria:~* Prior exposure to bortezomib~* Allogeneic transplantation scheduled as a part of the primary treatment~* Neuropathy \> Grade 2 (neurological symptoms interfering with ADL)~* Non-secreting myeloma~* Other concurrent disease making bortezomib treatment unsuitable~* Positive pregnancy test (only applicable for women with childbearing potential)~* Has known or suspected hypersensitivity or intolerance to boron, mannitol, or heparin, if an indwelling catheter is used~* Uncontrolled or severe cardiovascular disease including myocardial infarction within 6 months of enrolment, New York Heart Association (NYHA) Class III or IV heart failure (Attachment 6, NYHA Classification of Cardiac Disease), uncontrolled angina, clinically significant pericardial disease, or cardiac amyloidosis~* History of hypotension or has decreased blood pressure (sitting systolic blood pressure \[SBP\] £100 mmHg and/or sitting diastolic blood pressure \[DBP\] £60 mmHg)~* Serious medical or psychiatric illness likely to interfere with participation in this clinical study~* Have received an experimental drug or used an experimental medical device within 4 weeks prior to inclusion into the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- No treatment (Type: ACTIVE_COMPARATOR): None
- Bortezomib consolidation (Type: EXPERIMENTAL): Bortezomib consolidation : 20 injections starting 3 months after ASCT

Based on this trial design, predict the completion outcome and termination type (if applicable).